ReachRxResearch
Home
Research
Sign Up
Psilocybin and Inflammatory and Mitochondrial Stress Markers in Parkinson Disease
Back to Research Hub
  1. Home
  2. Research Hub
  3. Psilocybin and Inflammatory and Mitochon…

Psilocybin and Inflammatory and Mitochondrial Stress Markers in Parkinson Disease

JAMA Psychiatry·October 21Open Access
PsychiatryLimited evidenceMood DysfunctionParkinson DiseaseNonrandomized Clinical TrialPsychedelic-Assisted TherapyAdultPsilocybin

Summary

View source

What was studied

This nonrandomized clinical trial examined whether psilocybin therapy is associated with changes in systemic markers of inflammation and mitochondrial stress in people with Parkinson disease who also have mood dysfunction.

Study limitations

The nonrandomized design limits causal inference; the absence of a control group makes it difficult to distinguish treatment effects from natural disease progression or placebo response; the full text is not yet publicly available (PMC embargo until 2027-10-21), so specific results and sample size cannot be confirmed.

Clinical implications

Findings are not yet fully accessible; clinicians should await the full publication and peer review before drawing conclusions about psilocybin's effects on inflammation or mitochondrial stress in Parkinson disease.

Caveats

  • Several authors report financial relationships with psychedelic drug companies (Compass Pathways, Filament, Usona, Definium Therapeutics, MindMed, etc.), which may introduce bias
  • The full text is behind a PMC embargo until October 21, 2027; only the plain-language summary and metadata are available. No quantitative results, sample size, or detailed methods could be extracted
  • The nonrandomized design means observed changes in biomarkers cannot be confidently attributed to psilocybin rather than other factors such as disease progression or regression to the mean

Related Questions

Explore related topics

Psilocybin therapy for mood symptoms in Parkinson disease clinical trialsInflammatory biomarkers in Parkinson disease and neuropsychiatric comorbidityPsychedelics and mitochondrial function or oxidative stress in neurodegeneration

Publication Details

Year
2026
Journal
JAMA Psychiatry
Source
View article
Keep scrolling
More content below.
Up Next